Literature DB >> 28038356

mRNA overexpression of the hypoxia inducible factor 1 alpha subunit gene (HIF1A): An independent predictor of poor overall survival in chronic lymphocytic leukemia.

Christos K Kontos1, Sotirios G Papageorgiou2, Marios A Diamantopoulos3, Andreas Scorilas3, Efthimia Bazani2, Diamantina Vasilatou2, Konstantinos Gkontopoulos2, Eirini Glezou2, Georgia Stavroulaki2, George Dimitriadis2, Vasiliki Pappa4.   

Abstract

The hypoxia inducible factor 1 (HIF1) is a heterodimeric transcription factor that ultimately regulates cellular responses to changes in oxygen tension. In this study, we examined the potential diagnostic and prognostic potential of the mRNA expression of HIF1 regulatory α-subunit (HIF1A) in chronic lymphocytic leukemia (CLL). For this purpose, total RNA was isolated from peripheral blood mononuclear cells collected from 88 CLL patients and 33 non-leukemic blood donors, and poly(A)-RNA was reversely transcribed. HIF1A mRNA levels were quantified using real-time PCR. Kaplan-Meier survival analysis showed that high HIF1A mRNA expression predicts inferior overall survival for CLL patients (p=0.001). Bootstrap univariate Cox regression analysis confirmed that HIF1A mRNA overexpression is a significant unfavorable prognosticator in CLL (hazard ratio=3.75, bias-corrected and accelerated 95% confidence interval=1.43-24.36, bootstrap p<0.001), independent of other established prognostic factors, including CD38 expression, the mutational status of the immunoglobulin heavy chain variable region (IGHV), and the clinical stage (Binet or Rai stage) or risk group (p<0.001 in all cases). Interestingly, HIF1A mRNA positivity retains its unfavorable prognostic value in distinct subgroups of patients, stratified according to established prognostic factors. Thus, HIF1A mRNA overexpression can be regarded as a promising, independent molecular biomarker of unfavorable prognosis in CLL.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  CLL; Hematological malignancy; Prognostic biomarker; Real-time PCR; Tumor marker; Unfavorable prognosis

Mesh:

Substances:

Year:  2016        PMID: 28038356     DOI: 10.1016/j.leukres.2016.11.014

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  13 in total

1.  Alternative Splicing Detection Tool-a novel PERL algorithm for sensitive detection of splicing events, based on next-generation sequencing data analysis.

Authors:  Panagiotis G Adamopoulos; Margarita C Theodoropoulou; Andreas Scorilas
Journal:  Ann Transl Med       Date:  2018-06

Review 2.  Non-coding RNAs: the riddle of the transcriptome and their perspectives in cancer.

Authors:  Marios A Diamantopoulos; Panagiotis Tsiakanikas; Andreas Scorilas
Journal:  Ann Transl Med       Date:  2018-06

3.  PDK4 promotes tumorigenesis and cisplatin resistance in lung adenocarcinoma via transcriptional regulation of EPAS1.

Authors:  Shuo Yu; Yang Li; Hui Ren; Hong Zhou; Qian Ning; Xue Chen; Tinghua Hu; Lan Yang
Journal:  Cancer Chemother Pharmacol       Date:  2020-11-21       Impact factor: 3.333

Review 4.  Metabolic underpinnings of leukemia pathology and treatment.

Authors:  Travis Nemkov; Angelo D'Alessandro; Julie A Reisz
Journal:  Cancer Rep (Hoboken)       Date:  2018-10-07

5.  M2PP: a novel computational model for predicting drug-targeted pathogenic proteins.

Authors:  Shiming Wang; Jie Li; Yadong Wang
Journal:  BMC Bioinformatics       Date:  2022-01-04       Impact factor: 3.169

6.  Expression of hypoxia-inducible factor-1a predicts benefit from rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in diffuse large B-cell lymphoma.

Authors:  Jie Jin; Lihong Cao; Lijun Wang; Zhaoming Wang; Wei Ding; Liping Mao; Shanshan Suo; Zhengping Zhuang; Hongyan Tong
Journal:  Int J Clin Exp Pathol       Date:  2018-09-01

7.  Quantitative analysis and study of the mRNA expression levels of apoptotic genes BCL2, BAX and BCL2L12 in the articular cartilage of an animal model of osteoarthritis.

Authors:  Aristotelis Kourtis; Panagiotis G Adamopoulos; Apostolos Papalois; Dimitrios C Iliopoulos; George C Babis; Andreas Scorilas
Journal:  Ann Transl Med       Date:  2018-06

8.  MicroRNA-155-5p Overexpression in Peripheral Blood Mononuclear Cells of Chronic Lymphocytic Leukemia Patients Is a Novel, Independent Molecular Biomarker of Poor Prognosis.

Authors:  Sotirios G Papageorgiou; Christos K Kontos; Marios A Diamantopoulos; Anthi Bouchla; Eirini Glezou; Efthymia Bazani; Vasiliki Pappa; Andreas Scorilas
Journal:  Dis Markers       Date:  2017-12-31       Impact factor: 3.434

9.  HIF-1α is over-expressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia.

Authors:  Valentina Griggio; Candida Vitale; Maria Todaro; Chiara Riganti; Joanna Kopecka; Chiara Salvetti; Riccardo Bomben; Michele Dal Bo; Daniela Magliulo; Davide Rossi; Gabriele Pozzato; Lisa Bonello; Monia Marchetti; Paola Omedè; Ahad Ahmed Kodipad; Luca Laurenti; Giovanni Del Poeta; Francesca Romana Mauro; Rosa Bernardi; Thorsten Zenz; Valter Gattei; Gianluca Gaidano; Robin Foà; Massimo Massaia; Mario Boccadoro; Marta Coscia
Journal:  Haematologica       Date:  2019-07-09       Impact factor: 9.941

Review 10.  Targeting the Adenosinergic Axis in Chronic Lymphocytic Leukemia: A Way to Disrupt the Tumor Niche?

Authors:  Tiziana Vaisitti; Francesca Arruga; Silvia Deaglio
Journal:  Int J Mol Sci       Date:  2018-04-12       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.